<DOC>
	<DOCNO>NCT00907751</DOCNO>
	<brief_summary>Multicentric non-randomized phase II open prospective study ( 10 centre involve ) . Primary endpoint : - To evaluate kinetics B-cell depletion rituximab pharmacokinetics patient treat rituximab association plasma exchange . Secondary endpoint : - To evaluate tolerance rituximab , volume plasma number plasma exchange session require achieve durable complete remission , determinate duration B-cell depletion . - To evaluate incidence persistent severe acquire ADAMTS13 deficiency follow treatment rituximab , well incidence relapse .</brief_summary>
	<brief_title>Rituximab Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura</brief_title>
	<detailed_description>Duration study : 3 year 2 month , include 1 year inclusion 2 year participation patient . Experimental plan : Patients fulfil inclusion criterion study treat accord recommendation Reference Centre management thrombotic microangiopathies . If patient present refractory TTP , infusion rituximab ( 375 mg/m2 ) add treatment day 1 , 4 15 , immediately plasma exchange sessions.On diagnosis , treatment remission achievement , follow value explore : ADAMTS13 activity , ADAMTS13 inhibitors anti-ADAMTS13 antibody , B-cell lymphocytes quantification immunophenotyping , serum gammaglobulin level serum protein electrophoresis . Rituximab also quantify . Number patient : Each participate centre may recruit include 1 patient/year.Amongst 10 participate centre , total number 10 patient include . Specific activity study : Three infusion rituximab ( 375 mg/m2 /infusion ) , immediately plasma exchange session day 1 , 4 15 . Blood sampling day 1 , 4 15 , 1 month every 3 month month 24 . Expected result perspective : This study provide evidence whether association rituximab plasma exchange allo efficient B-cell depletion . If yes , randomize study perform evaluate role rituximab acute phase acquire idiopathic TTP , immediately diagnosis establish .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Microangiopathic hemolytic anemia ( &lt; 12 g/dL ) thrombocytopenia &lt; 50 G/L , mild renal failure ( Serum creatinine &lt; 150 µmol/L ) , negative Beta HCG ongoing contraception treatment 24 month follow last infusion rituximab , refractory TTP ( 4 day standard treatment ) &gt; 18 year old sign write informed consent . Hemolytic uremic syndrome ( platelet count ³ 50 G/L serum creatinine ³ 150 micromol/L ) , TTP associate another condition ( HIV infection , cancer and/or chemotherapy , transplantation ) , previous treatment vincristine cyclophosphamide immunomodulatory drug ( except steroid ) , within 2 month inclusion ; ongoing plan pregnancy , lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>